What are Protein subunit vaccine drugs?

Protein subunit vaccine drugs are pharmacologic agents that share a common mechanism (typically targeting SARS-CoV-2 spike protein). 3 are currently marketed, with 2 more in clinical development.

What are the marketed Protein subunit vaccine drugs?

Marketed Protein subunit vaccine drugs include MVC-COV1901(3 Months), protein subunit: Novavax COVID-19 vaccine, MVC-COV1901(6 Months).

Protein subunit vaccine

3 marketed 2 in Phase 3

This page covers all Protein subunit vaccine drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting SARS-CoV-2 spike protein, SARS-CoV-2 spike protein (S-2P).

Targets

SARS-CoV-2 spike protein · SARS-CoV-2 spike protein (S-2P)

Marketed (3)

MVC-COV1901(3 Months) · Taoyuan General Hospital · Immunology / Infectious Disease
MVC-COV1901 is a recombinant protein subunit vaccine that stimulates immune responses against SARS-CoV-2 spike protein to prevent COVID-19 infection.
protein subunit: Novavax COVID-19 vaccine · Novavax · Immunology / Infectious Disease
The Novavax COVID-19 vaccine delivers recombinant SARS-CoV-2 spike protein nanoparticles with an adjuvant to stimulate immune responses against the virus.
MVC-COV1901(6 Months) · Taoyuan General Hospital · Immunology / Infectious Disease
MVC-COV1901 is a recombinant protein subunit vaccine that stimulates immune responses against SARS-CoV-2 spike protein to prevent COVID-19 infection.

Phase 3 pipeline (2)

MVC-COV1901 · Medigen Vaccine Biologics Corp. · Immunology / Infectious Disease
MVC-COV1901 is a protein subunit vaccine that stimulates immune responses against SARS-CoV-2 by presenting viral spike protein antigens to the immune system.
Novavax COVID-19 Vaccine · Novavax · Immunology
Novavax COVID-19 Vaccine uses recombinant spike protein nanoparticles with a saponin-based adjuvant to stimulate immune responses against SARS-CoV-2.